title: Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.
abstract: BACKGROUND
  In patients with chronic hepatitis C (HCV) Interferon-alpha (IFN) treatment for 12-18 months is more effective than 6 months in inducing a sustained virological response.
  
  
  METHODS
  In a multicenter, randomized, controlled trial, 88 patients with chronic HCV were enrolled (47 treated with IFN-alpha2b and 41 constituted an untreated control group). Treatment consisted of 5 million units (MU) IFN thrice a week (tiw) for 8 weeks and subsequently 2.5 MU IFN tiw for 16 weeks ('standard treatment'). After week 24 ('long-term treatment'), in virological non-responders treatment was continued using 5 MU IFN tiw for up to week 156, whereas in virological responders IFN was discontinued. In case of a virological relapse, treatment with 5 MU IFN tiw was restarted and continued up to week 156.
  
  
  RESULTS
  Sustained virological response rate was 6/47 (13%) after standard treatment and increased to 19/47 (40%) after long-term treatment (McNemar paired test; P = 0.002). Of the 18 patients with a breakthrough or relapse during or after standard treatment, 14 (78%) became sustained virological responders upon long-term treatment. Of the 4 patients who did not have a sustained virological response after long-term treatment, 3 did not receive complete treatment due to side effects and/or non-compliance. In patients who failed to respond to standard treatment, no virological response was observed during long-term treatment. In the control group, no spontaneous clearance of HCV was observed.
  
  
  CONCLUSIONS
  Long-term IFN (re)treatment enhanced the virological sustained response rate significantly and was particularly effective in patients with a breakthrough or relapse following standard treatment.
authors.affiliation: Academic Medical Center, Dept of Liver Disease, Amsterdam The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Damen
authors.forename: C J
authors.initials: CJ
authors.lastname: Weegink
authors.forename: E P
authors.initials: EP
authors.lastname: Mauser-Bunschoten
authors.forename: H T
authors.initials: HT
authors.lastname: Cuypers
authors.forename: M C
authors.initials: MC
authors.lastname: Hermus
authors.forename: P
authors.initials: P
authors.lastname: Sillekens
authors.forename: E
authors.initials: E
authors.lastname: Haan
authors.forename: H M
authors.initials: HM
authors.lastname: van den Berg
authors.forename: D
authors.initials: D
authors.lastname: Bresters
authors.forename: P N
authors.initials: PN
authors.lastname: Lelie
authors.forename: R A
authors.initials: RA
authors.lastname: Chamuleau
authors.forename: H W
authors.initials: HW
authors.lastname: Reesink
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012008:Recurrence; D013997:Time Factors; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins